Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review
Journal of Clinical Medicine · 19.08.2026 · 15 (16) · 6423
DOI: 10.3390/jcm15166423 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.08.2026. Verfasst von Katarina Ivanovic und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Gynecology and Obstetrics, University Clinical Centre of Serbia, 11000 Belgrade, Serbia. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hypertensive disorders of pregnancy (HDP), particularly gestational hypertension and preeclampsia, are major causes of maternal and perinatal morbidity. Metabolic disorders such as gestational diabetes mellitus (GDM), type 2 diabetes mellitus (T2DM), obesity, and polycystic ovary syndrome (PCOS) share mechanisms with HDP, including insulin resistance, inflammation, oxidative stress, endothelial dysfunction, and placental maladaptation. Metformin may influence these pathways, but its clinical effect on hypertensive outcomes remains uncertain.
Methods
A focused narrative review was conducted using structured, targeted searches of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for literature published primarily from January 2015 through March 2026, supplemented by landmark studies, clinical guidelines, randomized trials, large observational cohorts, systematic reviews, meta-analyses, and mechanistic and placental studies. Evidence was selected for its relevance to the predefined phenotype-based framework and synthesized qualitatively across mechanistic, clinical, and translational domains.
Results
Metformin improves insulin sensitivity and may reduce gestational weight gain, metabolic stress, inflammatory signaling, and oxidative stress. Some randomized trials and meta-analyses in GDM, obesity, and PCOS suggest lower rates of pregnancy-induced hypertension or preeclampsia, whereas recent randomized and population-based studies report neutral effects. Findings are limited by heterogeneous populations, late treatment initiation, variable comparators, supplemental insulin use, inconsistent HDP definitions, and insufficient statistical power.
Conclusions
Metformin may act as a metabolic and vascular modifier in selected pregnancies, but current evidence does not support its routine use specifically for HDP prevention. Its public health value lies primarily in accessible metabolic treatment and integration into comprehensive antenatal and postpartum risk reduction pathways, rather than replacement of aspirin, blood pressure surveillance, or maternal–fetal monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic for Gynecology and Obstetrics, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
ORCID-Profile: Katarina Ivanovic, Stefan Dugalic, Miroslava Gojnic Dugalic, Milos Milincic
Zitieren
APA
Ivanovic, K., Dugalic, S., Gojnic Dugalic, M., & Milincic, M. (2026). Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review. Journal of Clinical Medicine, 15(16), 6423. https://doi.org/10.3390/jcm15166423
Vancouver
Ivanovic K, Dugalic S, Gojnic Dugalic M, Milincic M. Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review. Journal of Clinical Medicine. 2026;15(16):6423. doi:10.3390/jcm15166423
BibTeX
@article{Ivanovic2026,
author = {Ivanovic, Katarina and Dugalic, Stefan and Gojnic Dugalic, Miroslava and Milincic, Milos},
title = {Metformin and Hypertensive Disorders of Pregnancy: A Phenotype-Based Focused Narrative Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6423},
doi = {10.3390/jcm15166423}
}
EUVIMED